Xin Lang Cai Jing·2026-02-24 07:45Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Changzhou Pharmaceutical Factory Co., Ltd., has received a drug registration certificate from the Singapore Food and Drug Administration for the drug rivaroxaban, which has been approved for market launch [1] Group 1: Product Approval - The drug rivaroxaban is primarily used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation [1] - It is also indicated for the treatment and prevention of deep vein thrombosis (DVT), treatment of pulmonary embolism (PE), and prevention of venous thromboembolism (VTE) in acutely ill patients [1] Group 2: Investment and R&D - As of the announcement date, the company has invested approximately RMB 3.2482 million in research and development for this drug's market launch in Southeast Asia, specifically in Thailand, Singapore, Malaysia, and the Philippines [1]